Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Basic) (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed EPS (Basic) for 14 consecutive years, with -$0.16 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 82.98% year-over-year to -$0.16, compared with a TTM value of $5.31 through Sep 2025, up 105.39%, and an annual FY2024 reading of -$7.32, up 97.92% over the prior year.
  • EPS (Basic) was -$0.16 for Q3 2025 at Sunshine Biopharma, up from -$0.38 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $6.29 in Q4 2024 and bottomed at -$85.65 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$12.11, with a median of -$1.55 recorded in 2022.
  • The sharpest move saw EPS (Basic) crashed 237133.33% in 2023, then surged 107.34% in 2024.
  • Year by year, EPS (Basic) stood at -$4.73 in 2021, then skyrocketed by 67.26% to -$1.55 in 2022, then tumbled by 5430.04% to -$85.65 in 2023, then soared by 107.34% to $6.29 in 2024, then tumbled by 102.54% to -$0.16 in 2025.
  • Business Quant data shows EPS (Basic) for SBFM at -$0.16 in Q3 2025, -$0.38 in Q2 2025, and -$0.44 in Q1 2025.